Please login to the form below

Not currently logged in
Email:
Password:

New Lipitor indication reimbursements ineligible in South Korea

Pfizer will not make a request to the South Korean government to continue reimbursing Liptor when used for newly approved indications

According to local media reports, a spokesperson for US-based Pfizer has said the company will not make a request to the South Korean government to continue reimbursing Liptor (atorvastatin) when used for newly approved indications.

The spokesperson added that current government policy was unlikely to allow reimbursement for the additional indications of Lipitor, but that the company might change its mind should conditions change.

Pfizer made the decision because it was concerned that the government might cut the price of Lipitor later, if reimbursement coverage were expanded. The South Korean government tends to renegotiate the price of drugs after more indications become eligible for insurance reimbursement.

The Korea Food and Drug Administration (KFDA) recently approved six more indications, including stroke and cardiovascular risk reduction for the world's best-selling drug.

In July 2007, Pfizer projected FY07 Lipitor sales to be flat or down as much as five per cent from USD 12.9bn in FY06.

4th December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...

Infographics